Cannabinoid-1 Receptor Blockade in Cardiometabolic Risk Reduction: Efficacy

American Journal of Cardiology

Volumn 100, Issue 12 SUPPL. 1, 2007, Pages

  Aronne, Louis J ^a,b   Isoldi, Kathy Keenan ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; RIMONABANT; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN;

ANXIETY; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FOOD QUALITY; GLUCOSE METABOLISM; HEART MUSCLE METABOLISM; HUMAN; INCIDENCE; INSOMNIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; MONOTHERAPY; MOOD DISORDER; NAUSEA; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RISK FACTORS; TREATMENT OUTCOME;

EID: 37249010125     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.10.010     Document Type: Article

References (43)

1. Ogden C., Carroll M., Curtin L., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
2. Bray G. Medical consequences of obesity 2004. J Clin Endocrinol Metab 89 (2004) 2583-2589
3. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 3 (2006) 35-42
4. American Heart Association. AHA Statistical Update: Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
5. Bergman R.N., Kim S.P., Hsu I.R., et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular disease. Am J Med 120 (2007) 53-58
6. Déspres J.P., Lemieux I., and Prud'homme D. Treatment of obesity: need to focus on high-risk abdominally obese patients. BMJ 322 (2001) 716-720
7. Korner J., and Aronne L.J. The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest 11 (2003) 565-570
8. Pralong F., and Gaillard R.C. Neuroendocrine effects of leptin. Pituitary 4 (2001) 25-32
9. Wellen K., and Hotamisligil G. Inflammation, stress and diabetes. J Clin Invest 115 (2005) 1111-1119
10. Lau D., Dhillon B., Yan H., Szmitko P., and Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288 (2005) H2031-H2041
11. Goldstein B., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 (2004) 2563-2568
12. Eckel R., Kahn R., Robertson R.M., and Rizza R. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 113 (2006) 2943-2946
13. Kahn R., Buse I., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
14. Lorenzo C., Williams K., Hunt K.J., and Haffner S.M. The National Cholesterol Education Program Adult Treatment Panel III, International Diabetes Federation and World Health Organization definition of the metabolic syndrome as a predictor of incident CVD. Diabetes Care 30 (2007) 8-13
15. National Heart, Lung, and Blood Institute Obesity Education Initiative. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (2000), National Heart, Lung and Blood Institute, Bethesda, MD. www.nhlbi.nih.gov/guidelines/obesity/practgde.htm Accessed April 10, 2007
16. Li Z., Maglione M., Tu W., Majica W., Arterburn D., Shugarman L., Hilton L., Suttorp M., Solomon V., Shekelle P., and Morton S. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142 (2005) 532-546
17. Padwal R., and Majumdar S. Drug treatments for obesity: orlistat, sibutramine and rimonabant. Lancet 369 (2007) 71-76
18. Lowe M.R. Self-regulation of energy intake in the prevention and treatment of obesity: is it feasible?. Obes Res 11 suppl (2003) 45S-59S
19. Dansinger M., Gleason J., Griffith J., Selker H., and Schaefer E. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293; (2005) 43-53
20. Wadden T., Berkowitz R., Womble L., Sarwer D., Phelan S., Cato R., Hessen L., Osei S., Kaplan R., and Stunkard A. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353 (2005) 2111-2120
21. Hofbauer K., Nicholson J., and Boss O. The obesity epidemic: current and future pharmacological treatment. Annu Rev Pharmacol Toxicol 47 (2007) 565-592
22. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27 (2006) 73-100
23. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 (2006) 389-462
24. Bramlage P., Muhlen I., Randeva H., Spanswick D., and Lehnert H. Cardiovascular risk management by blocking the endocannabinoid system. Exp Clin Endocrinol Diabetes 114 (2006) 75-81
25. Kyrou J., Valsamakis G., and Tsigos C. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann N Y Acad Sci 1083 (2006) 270-305
26. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46 (2006) 101-122
27. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Janke J., Batkai S., Pacher P., Harvey-White J., Luft F., Sharma A., and Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005) 2838-2843
28. ob mice. Int J Obes 29 (2005) 183-187
29. Osei-Hyiaman D., Harvey-White J., Batkai S., and Kunos G. The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes 30 (2006) 533-538
30. Henness S., Robinson D., and Lyseng-Williamson K.A. Rimonabant. Drugs 66 (2006) 2109-2119
31. Pi-Sunyer F.X., Aronne L.J., Heshmate H., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 295 (2006) 761-775
32. Van Gaal L.F., Rissanen A., Scheen A., Ziegler O., and Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
33. Després J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
34. Scheen A., Finer N., Hollander P., Jensen M., and Van Gaal L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 368 (2006) 1660-1672
35. Manson J., Skerrett P., Greenland P., and VanItallie T. The escalating pandemics of obesity and sedentary lifestyle: a call to action for clinicians. Arch Intern Med 164 (2004) 249-258
36. Curioni C., and André C. Rimonabant for overweight or obesity (2006). www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006162/frame.html Accessed April 10, 2007
37. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R., and UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complication of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
38. Nainggolan L. SERENADE confirms efficacy of rimonabant in diabetes. [Medscape Web site.] (2006). www.medscape.com/viewarticle/548932 Accessed April 10, 2007
39. Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Subjects (ARPEGGIO). [ClinicalTrials.gov. http://www.clinicaltrials.gov/ct/show/NCT00288236?order=1 Accessed April 10, 2007
40. Rimonabant in Prediabetic Subjects to Delay Onset of Type 2 Diabetes (RAPSODI). [ClinicalTrials.gov Web site.]. http://www.clinicaltrials.gov/ct/show/NCT00325650?order=1 Accessed April 10, 2007
41. Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant-the Intravascular Ultrasound Study (STRADIVARIUS). [ClinicalTrials.gov Web site.]. http://www.clinicaltrials.gov/ct/show/NCT00124332?order=1 Accessed April 10, 2007
42. Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant (AUDITOR) trial. [ClinicalTrials.gov Web site.]. http://www.clinicaltrials.gov/ct/show/NCT00228176?order=1 Accessed April 10, 2007
43. Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes (CRESCENDO). [ClinicalTrials.gov Web site.]. http://www.clinicaltrials.gov/ct/show/NCT00263042?order=1 Accessed April 2, 2007